Compare Crispr Therapeutics AG (CRSP) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Marvell Technology Inc — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while Marvell Technology Inc trades at $222.9 (market cap $195.25B). The key difference: Marvell Technology Inc is far larger — about 39.3× Crispr Therapeutics AG's market cap, and Marvell Technology Inc pays a 0.11% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MRVL | |
|---|---|---|
Market Cap | $4.97B | $195.25B |
Sector | Health | Technology |
52-Week High | $76.78 | $316.43 |
52-Week Low | $44.34 | $62.31 |
Enterprise Value | $3.32B | $196.68B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Marvell Technology (MRVL) trades at $217.53, down 7.75% over the past day, reflecting recent market volatility. The stock shows strong analyst support with an 82% buy rating and a consensus price target of $275.68, indicating significant upside potential. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.80 surpassing the $0.798 estimate. However, the company reported a net loss of $885 million for 2025, though revenue grew to $5.77 billion. Technical indicators are bearish, with the price near key support at $213.
The outlook for MRVL is positive due to its positioning in custom AI chips and optical networking, with projected revenue growth to $8.7 billion in 2026. Risks include high valuation multiples (P/E of 74.75) and competitive pressures from peers like Nvidia and Broadcom. Investors should weigh the strong analyst optimism against fundamental challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
